M&A | Ophthalmology Innovation Source

How Thoughtful Consolidation Can Benefit Ophthalmology

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 014″] At the recent Ophthalmology Innovation Summit in Chicago, Jeff George, President & Global Head of Alcon; David E.I. Pyott, CEO of Allergan; Murthy V. Simhambhatla, PhD, President of Abbott Medical Optics; and

Ophthalmology Leaders Speak to Strength of Sector

A Wall Street Journal analysis of venture capital commitments showed ophthalmology remained the strongest sector within healthcare. According to the Wall Street Journal, privately held ophthalmology start-ups drew $442.7 million in capital over the first six months of this year, putting it on pace to surpass the $848.9 million raised in 2013. With the baby…

Avedro Broadens Cross-Link Product Line

Corneal collagen cross-linking has been a vexing specialty for US-based companies trying to guide a product through a cautious FDA. But Massachusetts-based Avedro Inc., continues to establish a meaningful portfolio in the space through deals like the acquisition of Switzerland-based IROC Innocross AG. Avedro acquired the assets of IROC Innocross, which was the first company…

Innovation Cycle Overview & Financing Environment Update

Presenter: William J. Link, PhD Bill was Founder, Chairman and CEO of Chiron Vision, sold in 1997. Bill founded and served as President of American Medical Optics (AMO), sold in 1986. View Full Profile

EU Commercialization Strategies

Summit Co-Chair and Managing Director for InterWest Partners, Gilbert Kliman MD, captures the audience’s thoughts on commercialization strategies in Europe through a series of live polling questions. Also gaining the expert opinions of panelists, Laurent Attias, David Muller, David E.I. Pyott, Jim Mazzo and Andy Corley, Gil compares the who, what and where questions that…

Jonathan Norris Predicts a Positive Cycle in the Ophthalmic Private Market

Private Funding and Exit Trends Jonathan Norris, Managing Director for SVB Capital, takes the stage to share the positive sentiments on the private markets. Highlighting in detail venture healthcare funds, Series A and M&A, Jonathan predicts stability in fundraising dollars, while investment dollars in the companies will begin to decline, expanding on the important role…

Alternative Financing Strategies

Charles Warden, Managing Director for Versant Ventures, initiates this finance focused panel by detailing the funding gap that has been referred to often at the 5th Annual Ophthalmology Innovation Summit @ AAO. Gaining insights from Luke Duster of Capital Royalty, Gregory Shearer of Healthios Capital Markets, Brian Demmert of Armentum Partners and Buzz Benson of…